Tempus AI, Inc. Class A ( (TEM) ) has risen by 15.42%. Read on to learn why.
Claim 30% Off TipRanks
New trading tool for TEM bullsTempus AI, Inc. Class A has enjoyed a strong week in the market, with its share price climbing 15.42% as investors piled into the fast-growing intersection of artificial intelligence and healthcare. The stock’s move comes despite a year-to-date decline and a technical “Strong Sell” signal, suggesting sentiment is being driven more by fresh catalysts and long‑term growth expectations than by short‑term trading indicators.
A major driver of the rally was the launch of Tempus AI’s new pan‑cancer HRD‑RNA algorithm, which uses RNA sequencing to detect homologous recombination deficiency — a key marker for predicting which cancer patients may respond better to targeted therapies such as PARP inhibitors. The tool showed strong performance in internal studies, closely aligning with established DNA-based HRD tests, and is expected to be fully available for clinical use in 2026. This breakthrough reinforced Tempus AI’s position as a leader in precision oncology diagnostics and AI‑enabled healthcare data.
Wall Street’s growing attention has added fuel to the move. Both Mizuho and Baird initiated coverage of Tempus AI with Outperform ratings, highlighting a roughly $40 billion and rapidly expanding market for precision oncology and therapy selection, and arguing that current valuations still discount the company’s growth potential. At the same time, high‑profile investor Cathie Wood’s ARK Investment has been actively buying shares, while analysts, on average, see substantial upside ahead of the company’s upcoming Q4 2025 earnings, where revenue is expected to surge and losses to narrow. Together, these factors have helped push Tempus AI, Inc. Class A sharply higher over the past week.